Mumbai, May 9 -- Revenue from operations shed 0.91% YoY to Rs 153.05 crore in Q4 FY26, compared with Rs 154.47 crore in the corresponding quarter last year.
The company posted a pre-tax loss of Rs 20.80 crore during the quarter against a profit before tax of Rs 11.72 crore in Q4 FY25.
EBITDA stood at Rs 25.33 crore in the quarter ended 31 March 2026, down 1.17% year on year (YoY). The EBITDA margin improved to 16.7% in Q4 FY26, as against 16.4% posted in Q4 FY25.
Segment-wise, domestic API revenue declined 2.56% year-on-year to Rs 86.85 crore, while API exports fell 5.42% to Rs 38.54 crore. Revenue from the formulations business rose 27.67% to Rs 27.67 crore during the quarter.
The said its novel anti-epileptic molecule, Cenobamate, i...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.